» Articles » PMID: 30376091

Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at Least 2 Doses

Abstract

Background: As a risk-mitigation strategy to minimize paralytic polio following withdrawal of Sabin type 2 from the oral poliovirus vaccine in April 2016, a single full dose or 2 fractional doses of inactivated poliovirus vaccine (IPV) are recommended. However, limited knowledge exists on long-term persistence of immune memory following 1- or 2-dose IPV schedules.

Methods: We examined induction and maintenance of immune memory following single- vs 2-dose IPV schedules, either full-dose intramuscular or fractional-dose intradermal, in rhesus macaques. Humoral responses, bone marrow-homing antibody-secreting plasma cells, and blood-circulating/lymph node-homing memory B cells were examined longitudinally.

Results: A single dose of IPV, either full or fractional, induced binding antibodies and memory B cells in all vaccinated macaques, despite failing to induce neutralizing antibodies (NT Abs) in many of them. However, these memory B cells declined rapidly, reaching below detection in the systemic circulation by 5 months; although a low frequency of memory B cells was detectable in draining lymph nodes of some, but not all, animals. By contrast, a 2-dose vaccination schedule, either full or fractional, efficiently induced NT Abs in all animals along with bone marrow-homing plasma cells and memory B cells. These memory B cells persisted in the systemic circulation for up to 16 months, the maximum duration tested after the second dose of vaccination.

Conclusions: Two doses of IPV, regardless of whether fractional or full, are more effective than a single dose for inducing long-lasting memory B cells.

Citing Articles

Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis?.

Devaux C, Pontarotti P, Levasseur A, Colson P, Raoult D Front Public Health. 2024; 11:1284337.

PMID: 38259741 PMC: 10801389. DOI: 10.3389/fpubh.2023.1284337.


Serological investigation on the prevalence of poliovirus in Guangdong province: A cross-sectional study.

Chen L, Qiu Q, Zhu Q, Li J, Xie X, Shao X Hum Vaccin Immunother. 2024; 20(1):2300156.

PMID: 38189143 PMC: 10793669. DOI: 10.1080/21645515.2023.2300156.


Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.

Sharma A, Verma H, Estivariz C, Bajracharaya L, Rai G, Shah G Lancet Microbe. 2023; 4(11):e923-e930.

PMID: 37774729 PMC: 10976347. DOI: 10.1016/S2666-5247(23)00215-X.


Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.

Van Tilbeurgh M, Lemdani K, Beignon A, Chapon C, Tchitchek N, Cheraitia L Vaccines (Basel). 2021; 9(6).

PMID: 34205932 PMC: 8226531. DOI: 10.3390/vaccines9060579.


Safety and Immunogenicity of a New Inactivated Polio Vaccine Made From Sabin Strains: A Randomized, Double-Blind, Active-Controlled, Phase 2/3 Seamless Study.

Capeding M, Gomez-Go G, Oberdorfer P, Borja-Tabora C, Bravo L, Carlos J J Infect Dis. 2020; 226(2):308-318.

PMID: 33351072 PMC: 9400411. DOI: 10.1093/infdis/jiaa770.


References
1.
Resik S, Tejeda A, Sutter R, Diaz M, Sarmiento L, Alemani N . Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013; 368(5):416-24. DOI: 10.1056/NEJMoa1202541. View

2.
Silveira E, Kasturi S, Kovalenkov Y, Rasheed A, Yeiser P, Jinnah Z . Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies. J Immunol Methods. 2014; 416:69-83. PMC: 4324134. DOI: 10.1016/j.jim.2014.11.003. View

3.
Morales M, Tangermann R, Wassilak S . Progress Toward Polio Eradication - Worldwide, 2015-2016. MMWR Morb Mortal Wkly Rep. 2016; 65(18):470-3. DOI: 10.15585/mmwr.mm6518a4. View

4.
Sutter R, Bahl S, Deshpande J, Verma H, Ahmad M, Venugopal P . Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet. 2015; 386(10011):2413-21. DOI: 10.1016/S0140-6736(15)00237-8. View

5.
Estivariz C, Pallansch M, Anand A, Wassilak S, Sutter R, Wenger J . Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. 2013; 3(3):309-15. PMC: 10395005. DOI: 10.1016/j.coviro.2013.05.007. View